On February 2, 2026, Harold Bernstein, the Chief Medical Officer and President of Research & Development at Maze Therapeutics (NASDAQ: MAZE), completed a significant transaction involving 15,000 shares. The CMO converted 15,000 stock options into shares and then immediately liquidated the entire